This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/drug/DB09014/identifier/kegg-drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB09014/identifier/drugbank/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/patent/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n10http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://www.drugs.com/international/
n8http://linked.opendata.cz/resource/drugbank/drug/DB09014/identifier/wikipedia/
n13http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB09014
rdf:type
n3:Drug
n3:description
Captodiame, also known as captodiamine, is an antihistamine which is used as a sedative and anxiolytic. It is a derivative of diphenhydramine. Captodiame has been suggested for use in preventing benzodiazepine withdrawal syndrome.
n3:generalReferences
# Mercier-Guyon C, Chabannes JP, Saviuc P: The role of captodiamine in the withdrawal from long-term benzodiazepine treatment. Curr Med Res Opin. 2004 Sep;20(9):1347-55. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15383182 # http://chem.sis.nlm.nih.gov/chemidplus/rn/486-17-9 # PENTNEY BH, BROTHERWOOD RW: Captodiame in anxiety states in general practice. Practitioner. 1960 Aug;185:218-21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14431646
n3:group
approved investigational
n3:indication
Captodiame is indicated for the treatment of anxiety.
owl:sameAs
n7:DB09014
dcterms:title
Captodiame
adms:identifier
n5:D07316 n8:Captodiame n11:DB09014
n3:patent
n16:2830088
n3:routeOfElimination
Renal.
n3:synonym
2-[(4-butylsulfanylphenyl)-phenyl-methyl]sulfanyl-N,N-dimethylethanamine Captodiame
n3:toxicity
-TDLo oral 17mg/kg (human) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX). PMID: 13535337. -LD50 intraperitoneal 116mg/kg (mouse) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD. PMID: 13062090. -LD50 intravenous 72mg/kg (mouse) BEHAVIORAL: ATAXIA. PMID: 14109651.
n3:salt
n3:synthesisReference
Captodiamine synthesis: Hubner Oluf Herman, Petersen Povl Viggo. U.S. Patent 2,830,088 (1958).
foaf:page
n15:captodiame.html
n3:IUPAC-Name
n10:271B64D5-363D-11E5-9242-09173F13E4C5
n3:InChI
n10:271B64DB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n10:271B64DA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n10:271B64D7-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n10:271B64D8-363D-11E5-9242-09173F13E4C5
n3:SMILES
n10:271B64D9-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n10:271B64D3-363D-11E5-9242-09173F13E4C5
n3:logP
n10:271B64D4-363D-11E5-9242-09173F13E4C5 n10:271B64D1-363D-11E5-9242-09173F13E4C5
n3:logS
n10:271B64D2-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n13:N05BB02
n3:H-Bond-Acceptor-Count
n10:271B64E1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n10:271B64E2-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n10:271B64DC-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n10:271B64DD-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n10:271B64DF-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n10:271B64DE-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n10:271B64E0-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
486-17-9
n3:Bioavailability
n10:271B64E6-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n10:271B64E8-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n10:271B64E9-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n10:271B64EA-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n10:271B64E5-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n10:271B64E4-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n10:271B64E7-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n10:271B64D6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n10:271B64E3-363D-11E5-9242-09173F13E4C5